ArticleEndocrine connections2025
Feasibility of transition research in pituitary disease using patient registries: a EuRREB secondary survey.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Rare disease registries focusing on natural history provide an opportunity to understand the transition process for rare endocrine conditions, including pituitary diseases. This study aims to assess the feasibility of using the European Registry for Rare Endocrine & Bone Conditions (EuRREB) for transition research in pituitary disease and to establish basic clinical characteristics of transition-age pituitary patients managed at reference centers (RCs) within the European Reference Network for Rare Endocrine Conditions (Endo-ERN). Methods: Patients in the Core Registry of EuRREB aged between 14 and 24 years with a pituitary diagnosis were eligible for inclusion. Physicians were asked to fill out a secondary survey evaluating transition aspects. Descriptive statistics and non-parametric analysis (Kruskal-Wallis, Mann-Whitney) were used. Results: Of 106 eligible patients, 98 patients had a confirmed diagnosis. Secondary survey data were available for 79 patients (74%) across 6 RCs from 5 countries. 72/79 patients (91%) remained in active care, with a single patient lost or discharged from follow-up (each n = 1, 1.3%). 29/79 (36.7%) were already transferred to adult care. Transfer typically occurred at age 18 years and in a few patients up to 22 years. A documented transfer plan was reported for 11 patients (13.9%). Patient-reported outcomes were collected in ten patients (13.5%). Transition challenges were either care-related or patient-related. Conclusion: This study provides initial characterization of transition of care in rare pituitary diseases in Endo-ERN RCs, showing high follow-up but inconsistent use of plans, patient-reported outcome measures (PROMs), and documentation. Rare disease registries can act as a tool to understand the process and identify barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.